News & Media
Contact
About
Leadership
Origin
Science
Publications
Platform
Culture
Open Positions
News & Media
Contact
News & Media
Press Releases
November 5, 2024
Ring Therapeutics Announces New Strategic Partnerships with A*STAR and SERI to Establish Gene Therapy R&D Efforts in Singapore, a Growing Global Biotech Hub
October 22, 2024
Ring Therapeutics Presents Preclinical Data on Anellogy™ Platform at the 31st Annual European Society of Gene & Cell Therapy Conference
October 8, 2024
Ring Therapeutics to Present Opening Keynote Lecture at the 19th International Symposium on Preparative and Industrial Chromatography and Allied Techniques (SPICA) Conference
May 7, 2024
Ring Therapeutics Presents New Data on Anellogy™ Platform at the 27th Annual American Society of Gene & Cell Therapy Conference
April 22, 2024
Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy
April 1, 2024
Ring Therapeutics Publishes a Novel Gene Delivery Platform Based on the Commensal Human Anellovirus
October 24, 2023
Ring Therapeutics Presents New Data on Anellogy™ Platform at the 30th Annual European Society of Gene & Cell Therapy Congress
September 26, 2023
Ring Therapeutics Announces Two Late Breaker Presentations at the 30th Annual European Society of Gene & Cell Therapy Conference
June 7, 2023
Ring Therapeutics Announces Appointment of Bioprocess and Biomanufacturing Veteran Konstantin Konstantinov, Ph.D. as Chief Technology Officer
May 1, 2023
Ring Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategy
March 9, 2023
Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines
January 30, 2023
Ring Therapeutics Announces Appointment of Industry Veteran Christopher Wright, M.D., Ph.D. as Chief Medical Officer, Head of Translational Research
September 20, 2022
Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector™ Compositions
July 18, 2022
Ring Therapeutics Announces Three Presentations at the 41st Annual Meeting of the American Society for Virology (ASV)
July 6, 2022
Ring Therapeutics Publishes the First Human Anellovirus Structure with Key Insights on Its Assembly, Function and Immune Evasion Properties
May 3, 2022
Ring Therapeutics Announces Two Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 2, 2022
Ring Therapeutics Announces Publication Highlighting In Vivo Delivery and Tropism of the First Synthesized Human Anelloviruses Using a Recombinant Genome
March 31, 2022
Ring Therapeutics Announces Publication Highlighting the Immune Favorability of Commensal Anelloviruses
March 17, 2022
Ring Therapeutics Announces the Appointment of Industry Leaders to its Board of Directors
November 8, 2021
Ring Therapeutics Strengthens Leadership Team with Three Executive Appointments
October 19, 2021
Ring Therapeutics Presents Data on Anellogy Platform at the ESGCT 28th Annual Congress
September 27, 2021
Fierce Biotech names Ring Therapeutics as one of its “Fierce 15” Biotech Companies of 2021
August 11, 2021
Ring Therapeutics Publishes New Research Mapping a Vast Number of Anelloviruses That May Hold the Key to the Next Generation of Gene Therapies
July 28, 2021
Ring Therapeutics Raises $117 Million in Series B Funding to Expand Novel Vector Platform to Unlock the Full Potential of Gene Therapy
October 14, 2020
Flagship Pioneering Announces Appointment of Tuyen Ong as CEO-Partner
December 19, 2019
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
Media Coverage
July 31, 2024
CGT Live
Chris Wright, MD, PhD, on Anelloviruses, a Potential Alternative to AAV for Gene Therapy
Chris Wright, MD, PhD
May 28, 2024
Nature
The immune system can sabotage gene therapies — can scientists rein it in?
Heidi Ledford
May 9, 2024
BiotechTV
Ring Therapeutics believes that the next great viral vector is a ubiquitous, but little known, family of viruses already found in the body
Brad Loncar
May 8, 2024
Fierce Biotech
ASGCT: Ring’s ‘new class of viral vector’ is re-dosable in primates, overcoming key challenge of AAVs
Helen Floersh
April 2, 2024
Fierce Biotech
In major step toward the clinic, Ring’s human viral vector delivers gene therapy to eyes of mice
Helen Floersh
February 28, 2024
Biotech 2050
Unlocking Genetic Medicine’s Full Potential
Tuyen Ong
December 11, 2023
Cell & Gene
Moving Beyond AAV: The Next Generation Of Vectors In CGT
Konstantin Konstantinov
June 6, 2023
Genetic Engineering & Biotechnology News
Derisking Genetic Medicines with NeuBase and Ring Therapeutics
Jonathan Grinstein
October 20, 2022
BioProcess International
Harnessing the Untapped Power of the Human Commensal Virome
Tuyen Ong
September 26, 2022
STAT
Biotech turns to new and strange viruses to overcome gene therapy’s limitations
Jason Mast
April 11, 2022
cellandgene.com – Business of Biotech Podcast
Commensal Viral Vectors With Ring Therapeutics’ Tuyen Ong, M.D.
Matt Pillar
May 26, 2022
CGTLive
Developing Safer Viral Vectors for Gene Therapy
Victoria Johnson
May 20, 2022
BioProcess Online
Will Anellovirus Vectors Solve Immunogenicity Challenges?
Matthew Pillar
January 5, 2022
Cell & Gene
Harnessing the Human Virome for the Next Generation of Gene Therapy Vectors
Tuyen Ong
November 15, 2021
Forbes
The Billionaire Chairman of Vaccine Maker Moderna Wants To Reinvent Scientific Entrepreneurship
Amy Feldman
November 12, 2021
Fierce Biotech
Chutes & Ladders
Kyle LaHucik
October 22, 2021
BioCentury
Gene Therapy’s Next Class of Biotechs
Lauren Martz
August 7, 2021
Chemical & Engineering News
Ring Therapeutics raises $117 million in series B funding
Megha Satyanarayana
August 4, 2021
BioSpace
Money on the Move: July 28 to August 3, 2021
Kate Goodwin
July 30, 2021
Barron’s
This Biotech Start-Up Hopes to Fix a Key Shortcoming of Gene Therapies
Bill Alpert
July 29, 2021
Boston Business Journal
Five things you need to know, and Boston’s tale of two cities
Doug Banks
July 29, 2021
The Science Advisory Board
Ring Therapeutics Nabs $117M for Vector Platform for Gene Therapy
July 29, 2021
Nature
Your Blood Teems with a Unique Set of Stealthy ‘Anelloviruses’
July 28, 2021
Global Genes
Ring Raises $117 Million to Advance Vector Platform to Unlock Full Potential of Gene Therapy
July 28, 2021
MedCity News
Ring Therapeutics Rounds Up $117M to Find Better Viral Vectors for Gene Therapy
Frank Vinluan
July 28, 2021
Fierce Biotech
Ring Therapeutics Calls In a Whopping $117M Series B for Gene Therapies
Kyle LaHucik
July 28, 2021
BioSpace
Ring Hopes to Bring First Re-dosable Gene Therapy to the Clinic with $117M Series B
Kate Goodwin
July 28, 2021
BioWorld
New Gene Therapy Approach from Ring Attracts $117M Series B Round
July 28, 2021
Fortune
TPG and Brookfield Add Billions to the Climate-Tech Coffers
Lucinda Shen
December 3, 2020
Nature Biology
People: Recent moves of note in and around the biotech and pharma industries
October 15, 2020
Endpoints News
Keeping an ‘Immigrant Mindset,’ Flagship Taps a Self-professed Nomad as CEO for their Next-gen Viral Vector Upstart
Max Gelman
October 14, 2020
Fierce Biotech
Ong Leaves Biogen to Become CEO-Partner at Flagship
Nick Paul Taylor
January 10, 2020
ISPE (Boston)
Ring Therapeutics to Use Novel Viruses to Deliver Gene Therapies
December 19, 2019
Xconomy (Boston)
Ring Therapeutics Launches to Expand Gene Therapy Viral Vector Options
December 19, 2019
STAT
Ring Therapeutics is Developing a New Way to Deliver Gene Therapy
Jonathan Saltzman
December 19, 2019
S&P Global
Flagship Pioneering Launches Biotechnology Company Ring Therapeutics
Murad Awan
December 19, 2019
BioCentury
Flagship Launches Ring with $50M, New Gene Therapy Vectors
Lauren Martz
